Decreased expression of speckle‑type POZ protein for the prediction of poor prognosis in patients with non‑small cell lung cancer

Li,Jing‑Jing; Zhang,Jian‑Feng; Yao,Su‑Mei; Huang,Hua; Zhang,Shu; Zhao,Minxing; Huang,Jian‑An

doi:10.3892/ol.2017.6567

Decreased expression of speckle‑type POZ protein for the prediction of poor prognosis in patients with non‑small cell lung cancer

Authors:
- Jing‑Jing Li
- Jian‑Feng Zhang
- Su‑Mei Yao
- Hua Huang
- Shu Zhang
- Minxing Zhao
- Jian‑An Huang
View Affiliations

Affiliations: Department of Respiratory Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China, Department of Gastroenterology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China, Department of Respiratory Medicine, The Second Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China, Department of Pathology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China, Department of Emergency, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China
Published online on: July 10, 2017 https://doi.org/10.3892/ol.2017.6567
Pages: 2743-2748
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Speckle‑type POZ domain protein (SPOP) has been acknowledged as a tumor suppressor gene in numerous types of cancer. However, SPOP expression and its prognostic role in human non‑small cell lung cancer (NSCLC) remain unknown. The present study investigated SPOP expression in NSCLC and evaluated its prognostic significance in patients with NSCLC. The results demonstrated that SPOP expression was significantly downregulated in NSCLC tissues at the mRNA and protein level compared with normal lung tissues using reverse transcription‑quantitative polymerase chain reaction, and western blot analysis. Immunohistochemical staining results also demonstrated that SPOP was expressed at a low level in 84.1% (132/157) of NSCLC samples and at a high level in 52.2% (12/23) of normal lung samples, whereby the difference was statistically significant (P<0.001). In addition, it was revealed that the level of SPOP was associated with histologic type (P=0.003), tumor differentiation (P=0.046), tumor size (P=0.0036), lymph node metastasis (P=0.041) and clinical stages (P=0.046). Furthermore, the overall survival of patients with high SPOP expression was significantly increased compared with that of patients with low SPOP expression (P=0.003). These results revealed that SPOP expression was downregulated in NSCLC tissues and associated with poor prognosis in patients with NSCLC, suggesting that SPOP is an independent prognostic marker candidate for NSCLC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
2	Zhang T, Zhang DM, Zhao D, Hou XM, Liu XJ, Ling XL and Ma SC: The prognostic value of osteopontin expression in non-small cell lung cancer: A meta-analysis. J Mol Histol. 45:533–540. 2014. View Article : Google Scholar : PubMed/NCBI
3	Esposito L, Conti D, Ailavajhala R, Khalil N and Giordano A: Lung cancer: Are we up to the challenge? Curr Genomics. 11:513–518. 2010. View Article : Google Scholar : PubMed/NCBI
4	Nagai Y, Kojima T, Muro Y, Hachiya T, Nishizawa Y, Wakabayashi T and Hagiwara M: Identification of a novel nuclear speckle-type protein, SPOP. FEBS Lett. 418:23–26. 1997. View Article : Google Scholar : PubMed/NCBI
5	De Marchis L, Cropp C, Sheng ZM, Bargo S and Callahan R: Candidate target genes for loss of heterozygosity on human chromosome 17q21. Br J Cancer. 90:2384–2389. 2004. View Article : Google Scholar : PubMed/NCBI
6	Hernández-Muñoz I, Lund AH, van der Stoop P, Boutsma E, Muijrers I, Verhoeven E, Nusinow DA, Panning B, Marahrens Y and van Lohuizen M: Stable X chromosome inactivation involves the PRC1 polycomb complex and requires histone MACROH2A1 and the CULLIN3/SPOP ubiquitin E3 ligase. Proc Natl Acad Sci USA. 102:7635–7640. 2005. View Article : Google Scholar : PubMed/NCBI
7	Kwon JE, La M, Oh KH, Oh YM, Kim GR, Seol JH, Baek SH, Chiba T, Tanaka K, Bang OS, et al: BTB domain-containing speckle-type POZ protein (SPOP) serves as an adaptor of Daxx for ubiquitination by Cul3-based ubiquitin ligase. J Biol Chem. 281:12664–12672. 2006. View Article : Google Scholar : PubMed/NCBI
8	Ande SR, Chen J and Maddika S: The ubiquitin pathway: An emerging drug target in cancer therapy. Eur J Pharmacol. 625:199–205. 2009. View Article : Google Scholar : PubMed/NCBI
9	Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, Yue P, Haverty PM, Bourgon R, Zheng J, et al: Diverse somatic mutation patterns and pathway alterations in human cancers. Nature. 466:869–873. 2010. View Article : Google Scholar : PubMed/NCBI
10	Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C, et al: The genomic complexity of primary human prostate cancer. Nature. 470:214–220. 2011. View Article : Google Scholar : PubMed/NCBI
11	Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, White TA, Stojanov P, Van Allen E, Stransky N, et al: Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 44:685–689. 2012. View Article : Google Scholar : PubMed/NCBI
12	Le GM, O'Hara AJ, Rudd ML, Urick ME, Hansen NF, O'Neil NJ, Price JC, Zhang S, England BM, Godwin AK, et al: Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet. 44:1310–1315. 2012. View Article : Google Scholar : PubMed/NCBI
13	Li C, Ao J, Fu J, Lee DF, Xu J, Lonard D and O'Malley BW: Tumor-suppressor role for the SPOP ubiquitin ligase in signal-dependent proteolysis of the oncogenic co-activator SRC-3/AIB1. Oncogene. 30:4350–4364. 2011. View Article : Google Scholar : PubMed/NCBI
14	Kim MS, Je EM, Oh JE, Yoo NJ and Lee SH: Mutational and expressional analyses of SPOP, a candidate tumor suppressor gene, in prostate, gastric and colorectal cancers. APMIS. 121:626–633. 2013. View Article : Google Scholar : PubMed/NCBI
15	Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JH, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, et al: The 2015 World Health Organization classification of lung tumors: Impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 10:1243–1260. 2015. View Article : Google Scholar : PubMed/NCBI
16	Edge SB and Compton CC: The American joint committee on cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Mani RS: The emerging role of speckle-type POZ protein (SPOP) in cancer development. Drug Discov Today. 19:1498–1502. 2014. View Article : Google Scholar : PubMed/NCBI
19	Ding D, Song T, Jun W, Tan Z and Fang J: Decreased expression of the SPOP gene is associated with poor prognosis in glioma. Int J Oncol. 46:333–341. 2015.PubMed/NCBI
20	Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, et al: The mutational landscape of lethal castration-resistant prostate cancer. Nature. 487:239–243. 2012. View Article : Google Scholar : PubMed/NCBI
21	Varshavsky A: Discovery of the biology of the ubiquitin system. JAMA. 311:1969–1970. 2014. View Article : Google Scholar : PubMed/NCBI
22	Pei XH, Bai F, Li Z, Smith MD, Whitewolf G, Jin R and Xiong Y: Cytoplasmic CUL9/PARC ubiquitin ligase is a tumor suppressor and promotes p53-dependent apoptosis. Cancer Res. 71:2969–2977. 2011. View Article : Google Scholar : PubMed/NCBI
23	Hoeller D and Dikic I: Targeting the ubiquitin system in cancer therapy. Nature. 458:438–444. 2009. View Article : Google Scholar : PubMed/NCBI
24	Cohen P and Tcherpakov M: Will the ubiquitin system furnish as many drug targets as protein kinases? Cell. 143:686–693. 2010. View Article : Google Scholar : PubMed/NCBI